Related Experiment Video
Updated: Apr 21, 2026
Author Spotlight: Expanding the Scope of Multiplex Immunoassays for Lyme Borreliosis Diagnostics and Pathogen Research
Published on: July 14, 2023
A concise critical analysis of serologic testing for the diagnosis of lyme disease
1Division of Pediatric Infectious Diseases, Children's National Health System, 111 Michigan Avenue, NW, West Wing 3.5, Suite 100, Washington, DC, 20010, USA, rdebiasi@cnmc.org.
Insights
Accurate Lyme disease diagnosis relies on clinical assessment in early stages and a two-tiered serologic testing approach for later stages. Understanding the strengths and limitations of these Lyme disease tests is crucial for effective patient care.
Area of Science:
- Medical Diagnostics
- Infectious Diseases
- Immunology
Background:
- Clinical diagnosis of Lyme disease often precedes serologic testing, especially in the early localized phase.
- Current diagnostic guidelines, like those from the CDC, recommend a two-tiered serologic approach for early disseminated and late Lyme disease.
- Serologic tests have limitations in sensitivity during the early stages of Lyme disease.
Purpose of the Study:
- To critically analyze the sensitivity, specificity, and predictive value of current serologic tests for Lyme disease.
- To review emerging diagnostic modalities for Lyme disease.
- To emphasize the importance of understanding diagnostic test performance for appropriate Lyme disease management.
Main Methods:
- Review of existing literature on Lyme disease diagnostic testing.
- Analysis of the performance characteristics (sensitivity, specificity, predictive value) of serologic assays.
- Discussion of alternative and emerging diagnostic methods, including IgG vlsE C6 peptide ELISA, other two-tiered strategies, rapid diagnostics, and PCR.
Main Results:
- Serologic testing for Lyme disease is less sensitive in the early localized phase, necessitating clinical diagnosis.
- The CDC-recommended two-tiered testing strategy involves ELISA followed by Western blot confirmation for indeterminate or positive results.
- Emerging tests like IgG vlsE C6 peptide ELISA and PCR are under evaluation for improved Lyme disease detection.
Conclusions:
- Appropriate diagnosis of Lyme disease requires careful consideration of the disease stage and the limitations of available serologic tests.
- Understanding the nuances of Lyme disease diagnostics is essential for clinicians.
- Further research into novel diagnostic modalities may improve early and accurate detection of Lyme disease.
Abstract:
Diagnostic testing for Lyme disease in the clinical setting primarily relies on assessment of serologic responses to infection, with the exception of the early localized phase of disease, in which the diagnosis must be made clinically, due to the recognized insensitivity of serologic testing at this phase of disease. For the diagnosis of early disseminated and late disease, the Centers for Disease Control and Prevention (CDC) recommends a two-tiered approach to testing consisting of initial IgM and IgG quantitative enzyme-linked immunosorbent assay (ELISA), followed by confirmation of all indeterminate or positive ELISA tests with separate IgG and IgM Western blots. This critical analysis addresses the sensitivity, specificity, and predictive value of serologic testing for Lyme disease in early localized, early disseminated, and late disease. Other testing modalities currently under evaluation are also discussed, including IgG vlsE C6 peptide ELISA, other two-tiered testing strategies, rapid diagnostics, and PCR. An understanding of the strengths and limitations of currently available testing for Lyme disease is critical for appropriate diagnosis.
